Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Antibe Therapeutics Inc(Pre-Merger) ATBPF

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.


GREY:ATBPF - Post by User

Post by MasterAlgaeon Apr 16, 2021 11:08am
137 Views
Post# 33010829

H2S, Antioxidant enhancement, and Cataract's in Cows

H2S, Antioxidant enhancement, and Cataract's in CowsMaster Algae has said in the past that The Covid was history, before we all heard of the UK variant, the Brazil variant, the South Africa variant, blood clots, etc etc.. - Master Algae was wrong again  - now it looks like The Covid is here to stay - with mutations being the norm in the foreseeable future. Africa and India will be the incubators for even newer variants, (another prediction!) Therefore - trials will have to commence around The Covid as the new normal.

MasterAlgae did some calculations based on the latest round of dilution from the  recent $6.00 bought deal, and the resultant 26% (or over $52,000,000) plunge in MC since that time. If the amalgamation results in 75 million shares, assuming there is no other progress made on partnership - then the share price it too terrible to put in print!

The CEO has stated that he doesn't care about the share price [day-to-day] - which is what he would say if his efforts were directed to navigating a drug to market - that is the target on a long voyage of many waypoints - and the market will follow, because markets-are-efficient. So he continues smiling-and-dialing! - some will know that phrase - although it pre-dates MasterAlgae it is a lovely term, as is, keep your finger in the hole - think rotary-phones. Ahhh..

Remember, Antibe has one product only - H2S Hydrogen Sulphide. Full stop. Period. Finito .

If the long, long, long awaited trial-results are frowned upon by the FDA - then the pipeline is bust - and the bid is a penny if we're lucky. Hail Mary! Would you shell out after-tax money on that? Well, if you're here you have! Gulp.

Obviously potential partners know this as well.

Google this for a fascinating read: Regulation of Cataractogenesis by Hydrogen Sulfide-NSAID Hybrid Compounds in Cultured Bovine Lenses



<< Previous
Bullboard Posts
Next >>